Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • Caribou Biosciences' Non Operating Income fell 4788.97% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 9055.4%. This contributed to the annual value of $17.5 million for FY2024, which is 2341.0% up from last year.
  • Per Caribou Biosciences' latest filing, its Non Operating Income stood at $1.9 million for Q3 2025, which was down 4788.97% from -$6.5 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Non Operating Income registered a high of $5.8 million during Q2 2024, and its lowest value of -$6.5 million during Q2 2025.
  • Over the past 5 years, Caribou Biosciences' median Non Operating Income value was $2.9 million (recorded in 2025), while the average stood at $2.0 million.
  • Per our database at Business Quant, Caribou Biosciences' Non Operating Income crashed by 294096.39% in 2021 and then skyrocketed by 1093125.0% in 2022.
  • Over the past 5 years, Caribou Biosciences' Non Operating Income (Quarter) stood at $2.2 million in 2021, then soared by 62.84% to $3.7 million in 2022, then dropped by 14.46% to $3.1 million in 2023, then increased by 7.86% to $3.4 million in 2024, then plummeted by 45.14% to $1.9 million in 2025.
  • Its Non Operating Income was $1.9 million in Q3 2025, compared to -$6.5 million in Q2 2025 and $2.9 million in Q1 2025.